Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Genes (Basel). 2019 Jul 24;10(8):557. doi: 10.3390/genes10080557.
The light sensing outer segments of photoreceptors (PRs) are renewed every ten days due to their high photoactivity, especially of the cones during daytime vision. This demands a tremendous amount of energy, as well as a high turnover of their main biosynthetic compounds, membranes, and proteins. Therefore, a refined proteostasis network (PN), regulating the protein balance, is crucial for PR viability. In many inherited retinal diseases (IRDs) this balance is disrupted leading to protein accumulation in the inner segment and eventually the death of PRs. Various studies have been focusing on therapeutically targeting the different branches of the PR PN to restore the protein balance and ultimately to treat inherited blindness. This review first describes the different branches of the PN in detail. Subsequently, insights are provided on how therapeutic compounds directed against the different PN branches might slow down or even arrest the appalling, progressive blinding conditions. These insights are supported by findings of PN modulators in other research disciplines.
感光器的光感外节由于其高的光活性,特别是在日间视觉中的锥体,每十天更新一次。这需要大量的能量,以及它们主要生物合成化合物、膜和蛋白质的高周转率。因此,一个精细的蛋白质稳定网络(PN),调节蛋白质平衡,对于 PR 的存活至关重要。在许多遗传性视网膜疾病(IRDs)中,这种平衡被打破,导致蛋白质在内节积累,最终导致 PR 死亡。各种研究一直专注于针对 PR PN 的不同分支进行治疗,以恢复蛋白质平衡,并最终治疗遗传性失明。本综述首先详细描述了 PN 的不同分支。随后,提供了关于针对不同 PN 分支的治疗化合物如何减缓甚至阻止惊人的进行性失明的见解。这些见解得到了其他研究领域中 PN 调节剂发现的支持。